Glickman Richard M

SEC source: 0000929638-26-002261 · form4.xml · derivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Common Shares · 31,000 shares

Expires 2036-06-16

F1 · derivative.exercise_date: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

SEC source: 0001104659-25-099652 · tm2528208-4_4seq1.xml · nonDerivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.

SEC source: 0000929638-25-002249 · form4.xml · derivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Shares · 22,500 shares

Expires 2035-06-16

F1 · derivative.exercise_date: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders.

SEC source: 0000929638-24-002214 · form4.xml · derivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires 2034-06-15

F1 · derivative.exercise_date: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders.

SEC source: 0000929638-24-002002 · form4.xml · derivative · entry 2

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 120 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

F2 · derivative.expiration_date: This option was originally due to expire December 4, 2023, however prior to that date the expiration date was extended to 120 days following the filing of enGene Holdings Inc.'s Form S-8, which was filed February 27, 2024. Accordingly, the option expiry date is June 26, 2024.

SEC source: 0000929638-24-002002 · form4.xml · nonDerivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950172-24-000233 · form4.xml · derivative · entry 2

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 3,750 shares

Expires 2024-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950172-24-000233 · form4.xml · nonDerivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950172-24-000134 · form4.xml · derivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Shares · 70,000 shares

Expires 2034-03-25

SEC source: 0000929638-23-002987 · form4.xml · nonDerivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,555

F1 · kind: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · kind: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F3 · kind: Reflects Common Shares acquired pursuant to the Business Combination.

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F3 · price: Reflects Common Shares acquired pursuant to the Business Combination.

SEC source: 0001209191-22-054968 · doc4.xml · derivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Shares · 35,000 shares

Expires 2032-06-29

F1 · derivative.exercise_date: 100% of the options vest after 12 months from the date of grant.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 9

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,001

Underlying: Common Shares · 12,001 shares

Expires 2031-08-20

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F11 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,500 common shares of enGene.

F11 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,500 common shares of enGene.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 8

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,205

Underlying: Common Shares · 14,205 shares

Expires 2031-08-20

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F10 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 78,712 common shares of enGene.

F10 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 78,712 common shares of enGene.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 7

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,032

Underlying: Common Shares · 12,032 shares

Expires 2030-12-14

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F9 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,667 common shares of enGene.

F9 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,667 common shares of enGene.

SEC source: 0001209191-21-002948 · doc4.xml · derivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2030-12-11

F1 · derivative.exercise_date: 25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter.

SEC source: 0001209191-21-005510 · doc4a.xml · derivative · entry 1

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2030-12-11

F1 · derivative.exercise_date: Vesting terms have been amended such that 100% of the options vest after 12 months from the date of grant.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 6

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,123

Underlying: Common Shares · 4,123 shares

Expires 2028-03-16

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F8 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 22,848 common shares of enGene.

F8 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 22,848 common shares of enGene.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 5

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,188

Underlying: Common Shares · 3,188 shares

Expires 2027-06-15

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F7 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 17,668 common shares of enGene.

F7 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 17,668 common shares of enGene.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 4

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,023

Underlying: Common Shares · 9,023 shares

Expires 2026-01-11

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F6 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 50,000 common shares of enGene.

F6 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 50,000 common shares of enGene.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 3

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,189

Underlying: Common Shares · 11,189 shares

Expires 2025-05-21

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F5 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 62,000 common shares of enGene.

F5 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 62,000 common shares of enGene.

SEC source: 0000929638-23-002987 · form4.xml · derivative · entry 2

Glickman Richard M · CIK 0001352637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120

Underlying: Common Shares · 120 shares

Expires 2023-12-04

F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".

F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F4 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 667 common shares of enGene.

F4 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 667 common shares of enGene.